AXSM - Axsome begins enrolling in late-stage study of migraine drug AXS-07

• Axsome Therapeutics ( NASDAQ: AXSM ) said it enrolled the first patient in a phase 3 trial of AXS-07 for the acute treatment of migraine.
• The study, dubbed EMERGE, will enroll ~100 patients to test the the efficacy and safety of AXS-07 in the acute treatment of migraine in patients with a prior inadequate response to an oral Calcitonin Gene-Related Peptide (CGRP) inhibitor.
• The two co-primary goals will be pain relief and absence of the most bothersome symptom two hours after dosing, the company said in a Sept. 1 press release.
• AXSM -2.38% to $62.28 premarket Sept. 1

For further details see: